Clene Inc. (CLNN) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.06, delivering a surprise of 14.29%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Clene, which belongs to the Zacks Medical - B ...

Exhibit 99.1 CLENE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) ● Peer-reviewed publication characterized the protein corona of CNM-Au8 ● Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access Program ● Cash, cash equivalents and ...

Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Peer-reviewed publication characterized the protein corona of CNM-Au8Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access ProgramCash, cash equivalents and marketable securities of $27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIRE) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 01-39834 | --- | --- | --- | --- | |------------------------------------------------------------------- ...

LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) --  via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ:CLNN), recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg ...

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8® 30 mg treatment (change from original baseline; p<0.05)Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observedFirst Phase 2 clinical MS trial ...

LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ:CLNN), recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. The podcast, hos ...

Proprietary catalytic gold nanocrystals comprising Clene's investigational drug CNM-Au8® develop a protein corona upon exposure to human blood plasma comprised of proteins that promote blood-brain barrier penetration, an important feature of the drug's neuroprotective mechanism of actionThe protein corona attracted by CNM-Au8 nanocrystals prevents aggregation upon entering the bloodstream, enabling the drug's longevity in circulation without provoking an inflammatory response SALT LAKE CITY, March 15, 2024 ...

Clene Inc. (CLNN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.02, delivering a surprise of 80%.Over the last four quarters, the company has surpassed consen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 01-39834 CLENE INC. (Exact name of registrant as specified in its charter) Delaware 85-2828339 (State or other jur ...